CDKN1A and medulloblastoma: Intensified RITA treatment did not increase CDKN1A expression, but increased MDM2 expression (P = 0.01) and activated the TP53 pathway in the xenograft tumor tissue (Figure 4C–4F), which corresponded well with our results for RITA treatment of medulloblastoma cell lines grown in vitro.